VIKING OBESITY POTENTIAL: H.C. Wainwright says Novo Nordisk’s REDEFINE-2 results reinforce Viking Therapeutics’ (VKTX) VK2735’s potential in obesity and beyond. Assuming full adherence ...

“It is our view that among investigated dual-acting agents (GLP-1/GIP, GLP-1/glucagon, GLP-1/amylin), the combination pursued by Eli Lilly’s Zepbound, Amgen’s MariTide, Viking’s VK2735 and ...

H.C. Wainwright says Novo Nordisk’s (NVO) REDEFINE-2 results reinforce Viking Therapeutics’ (VKTX) VK2735’s potential in obesity and beyond. Assuming full adherence, Novo’s CagriSema ...

I believe VK2735 has the potential to emerge as a best-in-class oral GLP-1 treatment. The Phase 2 trial readout for its oral formulation, expected in H2 2025, may be a defining moment for the ...

VKTX shares faltered in early February after a tepid earnings report, particularly concerning with its VK2735 experimental obesity-fighting drug. The company expects to roll out a final-phase ...

Twins with tattoos were more likely to get skin cancer and lymphoma Larger tattoos posed higher risk THURSDAY, March 6, 2025 (HealthDay News) -- People put a lot of thought into getting a tattoo ...

13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage ...

Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment ...

This bolstered the company's resources, enabling further investment in its pipeline. Viking's advancements in product development, particularly with its VK2735 and VK2809 trials, played a pivotal role ...

Raul Luis checks an order at his Birrieria Chalio Mexican Restaurant in Fort Worth, Texas, Thursday, Feb. 13, 2025. (AP Photo/LM Otero) Raul Luis checks an order at his Birrieria Chalio Mexican ...